国际骨质疏松基金会与欧洲钙化组织学会工作组:口服双膦酸盐依从性筛查建议
国际骨质疏松基金会与欧洲钙化组织学会工作组基于TRIO研究结果,建议在启动口服双膦酸盐治疗时及治疗3个月后检测骨转换标志物PINP和CTX,以识别依从性不佳的患者。若PINP下降超过38%或CTX下降超过56%(超过最小显著变化),提示治疗有效可继续;若无下降,临床医生应重新评估依从性及其他潜在问题。
要点
- 建议在基线及口服双膦酸盐治疗3个月后检测PINP和CTX。
- PINP下降超过38%或CTX下降超过56%提示治疗反应良好,可继续治疗。
- 若无显著下降,应重新评估依从性及药物相关问题。
核心结论
- 基于TRIO研究结果,工作组推荐在口服双膦酸盐治疗前及治疗3个月后检测PINP和CTX,以筛查依从性。
- 若PINP下降超过38%或CTX下降超过56%(超过最小显著变化),治疗可继续;若无下降,临床医生应重新评估以识别治疗问题,主要是依从性低。
研究设计与样本
- 国际骨质疏松基金会与欧洲钙化组织学会召集工作组,基于TRIO研究结果提出筛查策略,旨在回答骨转换标志物PINP和CTX能否用于识别起始口服双膦酸盐治疗的绝经后骨质疏松症患者依从性低的问题。
主要发现
- PINP的检测率为84%,CTX的检测率为87%,若同时测量两者并考虑至少一项变化,检测水平为94.5%。
关键数值与推荐
- 工作组推荐在基线及开始治疗后3个月测量PINP和CTX,检查是否出现超过最小显著变化的下降:PINP下降超过38%,CTX下降超过56%。
- PINP的检测率为84%,CTX的检测率为87%,同时测量两者并考虑至少一项变化时检测水平为94.5%。
临床怎么用
- 若观察到显著下降,治疗可继续;若无下降,临床医生应重新评估以识别治疗问题,主要是依从性低。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Adherence to oral bisphosphonates is low. A screening strategy is proposed based on the response of biochemical markers of bone turnover after 3 months of therapy. If no change is observed, the clinician should reassess the adherence to the treatment and also other potential issues with the drug. INTRODUCTION: Low adherence to oral bisphosphonates is a common problem that jeopardizes the efficacy of treatment of osteoporosis. No clear screening strategy for the assessment of compliance is widely accepted in these patients. METHODS: The International Osteoporosis Foundation and the European Calcified Tissue Society have convened a working group to propose a screening strategy to detect a lack of adherence to these drugs. The question to answer was whether the bone turnover markers (BTMs) PINP and CTX can be used to identify low adherence in patients with postmenopausal osteoporosis initiating oral bisphosphonates for osteoporosis. The findings of the TRIO study specifically address this question and were used as the basis for testing the hypothesis. RESULTS: Based on the findings of the TRIO study, specifically addressing this question, the working group recommends measuring PINP and CTX at baseline and 3 months after starting therapy to check for a decrease above the least significant change (decrease of more than 38% for PINP and 56% for CTX). Detection rate for the measurement of PINP is 84%, for CTX 87% and, if variation in at least one is considered when measuring both, the level of detection is 94.5%. CONCLUSIONS: If a significant decrease is observed, the treatment can continue, but if no decrease occurs, the clinician should reassess to identify problems with the treatment, mainly low adherence.
引用
- Diez-Perez A, Naylor KE, Abrahamsen B, et al. International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates. Osteoporos Int. 2017. PMID: 28093634. doi:10.1007/s00198-017-3906-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。